CD33KO-HSPC; CART33

Phase 1Biologic

UUniversity of Pennsylvania

CD33KO-HSPC; CART33 is one of 13 biologic programs targeting Leukemia, Myeloid, Acute. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leukemia, Myeloid, AcuteRecruiting

Leukemia, Myeloid, AcutePhase 1

Recruiting

Competition

Competitive Landscape

12 competitors in Leukemia, Myeloid, Acute

#DrugCompanyPhaseTrials

Peony

Takeda

Phase 3

1 2

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

5 3

Fludara

Sanofi

Phase 2

2 4

Cytosar

Teva

Phase 2

2 5

Trexall

Jazz Pharmaceuticals

Phase 2

1 6

Tepadina

Jazz Pharmaceuticals

Phase 2

1 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 8

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 9

Revuforj

SSyndax Pharmaceuticals

Phase 2

1 10

Mylotarg

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2044

Phase 1Recruiting

Leukemia, Myeloid, Acute

NCT05945849

Clinical

Trials by Indication[1]

Leukemia, Myeloid, Acute1 trial

Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCRζ And 4-1BB Signaling Domains In Combination With CD33KO-HSPC In Subjects With Refractory Or Relapsed Acute Myeloid Leukemia

Recruiting·UUniversity of Pennsylvania·Phase 1·NCT05945849·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD33KO-HSPC; CART33. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD33KO-HSPC; CART33 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD33KO-HSPC; CART33. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Pennsylvania

CD33KO-HSPC; CART33

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2044

Trials by Indication[1]

Leukemia, Myeloid, Acute1 trial

References

Drug Info

Quick Facts

Related News